Dr. Michael Mullan, president and CEO the Roskamp Institute noted that; “Both traumatic brain injury (TBI) and multiple sclerosis (MS) have in common massive brain inflammation. The reason anatabine looks so promising in both these conditions is likely because, as we have previously shown, it is a potent anti-inflammatory agent. Although anatabine’s anti-inflammatory activity may have different roles in each of these conditions the net result is to reduce the clinical and neuropathological consequences.”
Scientists at Roskamp Institute in Sarasota, Florida have conducted research with results that suggest anatabine may benefit people who have autoimmune disorders such as multiple sclerosis. Experiments were conducted using well established protocols in mice with pathologies typical of multiple sclerosis. Among the data recorded was the amount of inflammation on the spinal cord of control and anatabine treated mice during the acute phase of the disease. Results show a 86% effective rate in controlling inflammation and recovery from posterior hindlimb paralysis versus 34% in the placebo control population. Conclusions are that production of pro-inflammatory cytokines seem to be regulated with the administering of anatabine treated mice over the control which leads to greater recover from the paralysis condition. This study warrants further study especially associate with the chronic phase of multiple sclerosis and other autoimmune disorders.
According to the Centers for Disease Control, 80,000 people in the United States suffer long-term disability from a traumatic brain injury (TBI) annually. Roskamp Institute scientists conducted a research study of TBI and control mice by administering anatabine to measure its effectiveness for recovery from injury using scientific accepted methods. TBI mice treated with a placebo and the sham (untreated) mice recovered at a similar rate with deteriorated motor and cognitive functions. The anatabine treated mice however had a significant recovery the researchers believe, by inhibiting inflation and reducing amyloid production. To quote the published research paper; “Anatabine treatment appeared to completely prevent the loss of spatial memory retention following severe TBI. Further study of this promising treatment is warranted and will include treatment in a mild closed head injury model as well as long term outcome from injury. Dietary supplementation for reducing secondary injury after TBI offers an easy path to clinical application and simplifies the administration of the therapeutic.” This pathological information warrant further studies with ongoing research in exploring other models of TBI using anatabine.
Research study findings by Roskamp Institute were presented at Neuroscience 2012 about the impact of anatabine in treating Alzheimer’s disease (AD). AD is a neurodegenerative disorder that causes problems with memory and behavior due to the increasing death of nerve cells in the brain. Most scientists, supported by research done at Roskamp Institute, agree that excessive amyloid plaque buildup (Abeta peptides) and neurofibrillary tangles (twisted protein fibers named tau) are directly related to the brain nerve cell loss. Data from the study using a well-known mouse model of AD shows that anatabine treated mice have a significant reduction in the accumulation of plaque in the brain as compared to the control population. Scientists believe this occurs because anatabine reduces or regulates human neuronal like protein BACE-1 (the rate limiting enzyme responsible for Abeta production). Cognitive tests of an ongoing investigation of anatabine treated mice show greater cerebral functions and improved abilities as compared to the non-treated sample. Data from the study also show anatabine’s anti-inflammatory results. Anatabine reduces neuroinflammation and STAT3 phosphorylation in the brain of transgenic AD mice. Additional research is warranted based upon results of this study regarding the potential benefit of anatabine in the treatment of Alzheimer’s disease.